DataMeds AI, Inc. (MEDS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$90.54M

Year ended 2025-12-31

-$67.94M

Trailing 12 months to 2026-06-30

2024-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$90.54M	n/m	2026-03-20, From 2025-01-01
2024-12-31	-$5.03M	n/a	2026-03-20, From 2024-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Wholesale-Drugs, Proprietaries & Druggists' Sundries), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
DataMeds AI, Inc. (MEDS)	2025-12-31	-$90.54M	n/m
Cosmos Health Inc. (COSM)	2025-12-31	-$15.33M	n/m
Stemtech Corp (STEK)	2025-12-31	-$2.54M	n/m
Nu Skin Enterprises, Inc. (NUS)	2025-12-31	$118.02M	n/m
Herbalife Ltd. (HLF)	2025-12-31	$602.20M	+18.7%
Cardinal Health Inc (CAH)	2026-06-30	$3.57B	+16.4%
Cencora, Inc. (COR)	2025-09-30	$3.68B	+12.6%
McKesson Corp (MCK)	2026-03-31	$6.94B	+37.2%

Compare MEDS, COSM, STEK, NUS side by side · Screen every company in Wholesale-Drugs, Proprietaries & Druggists' Sundries ↗